IN2015DN03998A - - Google Patents
Info
- Publication number
- IN2015DN03998A IN2015DN03998A IN3998DEN2015A IN2015DN03998A IN 2015DN03998 A IN2015DN03998 A IN 2015DN03998A IN 3998DEN2015 A IN3998DEN2015 A IN 3998DEN2015A IN 2015DN03998 A IN2015DN03998 A IN 2015DN03998A
- Authority
- IN
- India
- Prior art keywords
- medicaments
- medicament
- substituents
- salt
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Inorganic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736748P | 2012-12-13 | 2012-12-13 | |
| PCT/IB2013/060859 WO2014091446A1 (fr) | 2012-12-13 | 2013-12-12 | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones utilisés en tant que suppresseurs de mutation non-sens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03998A true IN2015DN03998A (fr) | 2015-10-02 |
Family
ID=50030361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3998DEN2015 IN2015DN03998A (fr) | 2012-12-13 | 2013-12-12 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9649314B2 (fr) |
| EP (1) | EP2931282B1 (fr) |
| JP (1) | JP6076498B2 (fr) |
| KR (1) | KR101760586B1 (fr) |
| CN (2) | CN104837490B (fr) |
| AP (1) | AP2015008441A0 (fr) |
| AU (1) | AU2013358591B2 (fr) |
| BR (1) | BR112015013535A2 (fr) |
| CA (1) | CA2890692A1 (fr) |
| CL (1) | CL2015001610A1 (fr) |
| CR (1) | CR20150314A (fr) |
| CU (1) | CU20150061A7 (fr) |
| EA (1) | EA028673B1 (fr) |
| ES (1) | ES2709034T3 (fr) |
| HK (1) | HK1209637A1 (fr) |
| IL (1) | IL239244A0 (fr) |
| IN (1) | IN2015DN03998A (fr) |
| MA (1) | MA38157A1 (fr) |
| MX (1) | MX363437B (fr) |
| PE (1) | PE20151062A1 (fr) |
| PH (1) | PH12015501216A1 (fr) |
| SG (1) | SG11201503684WA (fr) |
| TN (1) | TN2015000262A1 (fr) |
| WO (1) | WO2014091446A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2015008441A0 (en) | 2012-12-13 | 2015-05-31 | Novartis Ag | Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors |
| BR112016027383A8 (pt) | 2014-06-03 | 2021-07-20 | Novartis Ag | derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação |
| CN106414443B (zh) * | 2014-06-03 | 2018-10-26 | 诺华股份有限公司 | 吡啶并嘧啶二酮衍生物 |
| ES2743184T3 (es) | 2014-06-03 | 2020-02-18 | Novartis Ag | Derivados de pirimido[4,5-b]quinolin-4,5(3H,10H)-diona como supresores de mutaciones finalizadoras |
| US10960018B2 (en) * | 2016-04-15 | 2021-03-30 | The Uab Research Foundation | Methods and compounds for stimulating read-through of premature termination codons |
| EP3762383B1 (fr) * | 2018-03-06 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Modulateurs allostériques positifs du récepteur de la dopamine 1 et procédé d'utilisation associé |
| WO2019225625A1 (fr) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | Inducteur de translecture et utilisation pharmaceutique associée |
| IL301285A (en) | 2020-09-10 | 2023-05-01 | Precirix N V | A portion of an antibody against FAP |
| EP4277901A1 (fr) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Composés d'isoindolinone |
| WO2023203135A1 (fr) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Anticorps radiomarqué amélioré |
| WO2023213801A1 (fr) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pré-ciblage |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (ja) * | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | ５−デアザフラビン系化合物を有効成分とする制癌剤 |
| US5908930A (en) | 1995-03-15 | 1999-06-01 | Pfizer Inc. | 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| WO2004006906A2 (fr) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methodes de traitement de neoplasmes |
| CA2514733A1 (fr) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
| EP1618098B1 (fr) | 2003-04-11 | 2014-11-19 | PTC Therapeutics, Inc. | Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies |
| EP2390255B1 (fr) | 2006-04-03 | 2016-07-13 | Technion Research & Development Foundation Ltd. | Nouveaux aminoglycosides et leurs utilisations dans le traitement de troubles génétiques |
| AU2007288198A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
| CA2709784A1 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
| EP2422817A1 (fr) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Conjugués flavine-ligand d'acide nucléique |
| CN103189060A (zh) * | 2010-08-05 | 2013-07-03 | 里尔法律与医疗卫生第二大学 | 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物 |
| AP2015008441A0 (en) | 2012-12-13 | 2015-05-31 | Novartis Ag | Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors |
-
2013
- 2013-12-12 AP AP2015008441A patent/AP2015008441A0/xx unknown
- 2013-12-12 BR BR112015013535A patent/BR112015013535A2/pt not_active Application Discontinuation
- 2013-12-12 AU AU2013358591A patent/AU2013358591B2/en not_active Ceased
- 2013-12-12 WO PCT/IB2013/060859 patent/WO2014091446A1/fr active Application Filing
- 2013-12-12 CN CN201380064035.5A patent/CN104837490B/zh not_active Expired - Fee Related
- 2013-12-12 US US14/652,102 patent/US9649314B2/en not_active Expired - Fee Related
- 2013-12-12 JP JP2015547244A patent/JP6076498B2/ja not_active Expired - Fee Related
- 2013-12-12 PE PE2015000911A patent/PE20151062A1/es not_active Application Discontinuation
- 2013-12-12 SG SG11201503684WA patent/SG11201503684WA/en unknown
- 2013-12-12 IN IN3998DEN2015 patent/IN2015DN03998A/en unknown
- 2013-12-12 MX MX2015007562A patent/MX363437B/es unknown
- 2013-12-12 KR KR1020157018231A patent/KR101760586B1/ko active IP Right Grant
- 2013-12-12 EP EP13826612.7A patent/EP2931282B1/fr active Active
- 2013-12-12 CA CA2890692A patent/CA2890692A1/fr not_active Abandoned
- 2013-12-12 CN CN201710826258.0A patent/CN107569487A/zh active Pending
- 2013-12-12 ES ES13826612T patent/ES2709034T3/es active Active
- 2013-12-12 EA EA201591105A patent/EA028673B1/ru not_active IP Right Cessation
-
2015
- 2015-05-29 PH PH12015501216A patent/PH12015501216A1/en unknown
- 2015-06-04 IL IL239244A patent/IL239244A0/en unknown
- 2015-06-05 MA MA38157A patent/MA38157A1/fr unknown
- 2015-06-09 TN TNP2015000262A patent/TN2015000262A1/fr unknown
- 2015-06-10 CL CL2015001610A patent/CL2015001610A1/es unknown
- 2015-06-12 CR CR20150314A patent/CR20150314A/es unknown
- 2015-06-12 CU CUP2015000061A patent/CU20150061A7/es unknown
- 2015-10-23 HK HK15110447.1A patent/HK1209637A1/xx unknown
-
2017
- 2017-04-04 US US15/478,778 patent/US20170266189A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03998A (fr) | ||
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| NZ608116A (en) | Triazine-oxadiazoles | |
| IN2014DN10449A (fr) | ||
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| PH12015501083B1 (en) | Novel pyridine derivatives | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| MX343706B (es) | Derivados heterocíclicos novedosos. | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| PH12015501843A1 (en) | Novel pyrazol derivatives | |
| IN2015DN01119A (fr) | ||
| IN2014DN01629A (fr) | ||
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| MY174000A (en) | Novel pyridine derivatives | |
| MX362879B (es) | Usos novedosos. | |
| MX2016004934A (es) | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| PH12015500585A1 (en) | Modified hyaluronic acid derivatives and use thereof | |
| IN2014DN10669A (fr) | ||
| MX363458B (es) | Nuevos derivados de tetrazolona. | |
| MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
| PH12015500373B1 (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease | |
| MX348841B (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| TN2013000089A1 (en) | Triazine-oxadiazoles | |
| MA37778A1 (fr) | Dérivés de carbamate/urée |